Top

International Journal of Clinical Pharmacy

Published in:

01-08-2021 | Tigecycline

Answers to the authors of the “Letter to the Editor”: A comparative study between non colistin based combinations for treatment of infections caused by extensive drug resistant Acinetobacter baumannii: comments

Author: Mohamed Ahmed Elarabi

Published in: International Journal of Clinical Pharmacy | Issue 4/2021

Excerpt

To the editor …

Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacterspp. J AntimicrobChemother. 2008;61(6):1369–75.

Ye JJ, Lin HS, Yeh CF, et al. Tigecycline-based versus sulbactam based treatment for pneumonia involving multidrug-resistant Acinetobactercalcoaceticus-Acinetobacterbaumannii complex. BMC Infect Dis. 2016;16:374.CrossRef

Jung SY, Lee SH, Lee SY, Yang S, Noh H, Chung EK, Lee JI. Antimicrobials for the treatment of drug-resistant Acinetobacterbaumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit Care. 2017;21(1):319.CrossRef

Chuang YC, Cheng CY, Sheng WH, et al. Effectiveness of tigecycline- based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacterbaumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102.CrossRef

Kim WY, Moon JY, Huh JW, Choi SH, Lim CM, Koh Y, Chong YP, Hong SB. Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacterbaumannii pneumonia in critically ill patients. PLoS ONE. 2016;11(3):e0150642.CrossRef

Zeina A, Kanafani M, Souha S, Kanj MD. Acinetobacter infection: treatment and prevention. UpToDate: Wolters Kluwer Clinical Drug Information, Inc., 2018. Retrieved 21 March 2018, from https://www.uptodate.com/contents/acinetobacter-infection treatment-and-prevention.

Antibiotic name. Lexicomp Online, Lexi-drugs online: Wolters Kluwer Clinical Drug Information, Inc., 2018.Available from: http://online.lexi.com. Subscription required to view.

Fishbain J, Peleg AY. Treatment of Acinetobacter Infections. Clin Infect Dis. 2010;51(1):79–84. https://doi.org/10.1086/653120.CrossRefPubMed

Qin Y, Zhang J, Wu L, Zhang D, Fu L, Xue X. Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator associated pneumonia caused by extensively drug-resistant Acinetobacterbaumannii. Int J ClinPharmacolTher. 2018;56(3):120–9.

10.

Assimakopoulos SF, Karamouzos V, Lefkaditi A, et al. Triple combination therapy with high-dose ampicillin/sulbactam, high dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacterbaumannii: a case series study. Infez Med. 2019;27(1):11–6.PubMed

11.

Liu B, Bai Y, Liu Y, et al. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacterbaumannii. J Chemother. 2015;27(5):271–6.CrossRef

12.

Temocin F, Erdinc FS, Tulek N, et al. Synergistic effects of sulbactam in multi-drug-resistant Acinetobacterbaumannii. Braz J Microbiol. 2015;46(4):1119–24.CrossRef

13.

Dong X, Chen F, Zhang Y, Liu H, Liu Y, Ma L. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter. J Antibiot. 2014;67(9):677–80.CrossRef

14.

TYGACIL® (TIGECYCLINE) FOR INJECTION [Internet]. Accessdata.fda.gov. 2010 [cited 24 August 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021821s010lbl.pdf

15.

CLINICAL PHARMACOLOGY & BIOPHARMACEUTICS REVIEW of Tigecycline (Tygacil™) [Internet]. Accessdata.fda.gov. 2005 [cited 24 August 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021821Orig1s000ClinPharmR.pdf

16.

SUMMARY OF PRODUCT CHARACTERISTICS of Tygacil 50 mg powder for solution for infusion [Internet]. Ema.europa.eu. [cited 24 August 2020]. Available from: https://www.ema.europa.eu/en/documents/product-information/tygacil-epar-product-information_en.pdf

17.

Tigecycline 50 mg powder for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. Medicines.org.uk. 2018 [cited 24 August 2020]. Available from: https://www.medicines.org.uk/emc/product/9232/smpc

18.

Moehring R, J Anderson D. Gram-negative bacillary bacteremia in adults [Internet]. Uptodate.com. 2020 [cited 24 August 2020]. Available from: https://www.uptodate.com/contents/gram-negative-bacillary-bacteremia-in-adults#H13

19.

UNASYN® (ampicillin sodium/sulbactam sodium) [Internet]. Accessdata.fda.gov. 2017 [cited 24 August 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050608s044lbl.pdf

20.

Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis. 1986;8((Supplement_5)):S503–11.CrossRef

21.

Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiellapneumoniae or MDR Acinetobacterbaumanniiurosepsis. J ClinMicrobiol. 2009;47(5):1613.

22.

Timsit JF, de Kraker ME, Sommer H, Weiss E, Bettiol E, Wolkewitz M, Nikolakopoulos S, Wilson D, Harbarth S. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE’s STAT-Net. Intensive Care Med. 2017;43(7):1002–12.CrossRef

23.

Malone M. Chapter 3 - The Microbiome of Diabetic Foot Ulcers and the Role of Biofilms [Internet]. sciencedirect. 2020 [cited 12 December 2020]. Available from: https://www.sciencedirect.com/science/article/pii/B9780128110799000033?via%3Dihub.

24.

Marston W. Chapter 20 - Venous Ulcers [Internet]. Atlas of Endovascular Venous Surgery Book, 2nd Edition. 2019 [cited 3 September 2020]. Available from: https://www.sciencedirect.com/science/article/pii/B9780323511391000206

25.

Piewngam P, Kiratisin P. Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacterbaumannii clinical isolates, including multidrug-resistant isolates. Int J Antimicrob Agents. 2014;44(5):396–401.CrossRef

26.

Şimşek M, Demir C. Determination of Colistin and Tigecycline Resistance Profile of AcinetobacterBaumannii Strains from Different Clinical Samples in a Territory Hospital in Turkey. J Health Sci Med Res. 2020;38(2):81–91.

27.

Spiliopoulou A, Jelastopulu E, Vamvakopoulou S, Bartzavali C, Kolonitsiou F, Anastassiou ED, Christofidou M. In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period. J Chemother. 2015;27(5):266–70.CrossRef

28.

Paul M, Scudeller L. Clinical research designs to study treatment effects for multidrug-resistant bacteria. ClinMicrobiol Infect. 2019;25(8):929–31.CrossRef

Title: Answers to the authors of the “Letter to the Editor”: A comparative study between non colistin based combinations for treatment of infections caused by extensive drug resistant Acinetobacter baumannii: comments
Author: Mohamed Ahmed Elarabi
Publication date: 01-08-2021
Publisher: Springer International Publishing
Keyword: Tigecycline
Published in: International Journal of Clinical Pharmacy / Issue 4/2021
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-020-01214-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2021

Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin

Understanding management of poorly controlled pain in community-dwelling analgesic users: a qualitative study

Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data

Risk factors for nephrotoxicity associated with polymyxin B therapy in Chinese patients

Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis

Trends in the consumption of antibiotics in the Lebanese community between 2004 and 2016

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage